Xu, Z.; Huang, A.; Luo, X.; Zhang, P.; Huang, L.; Wang, X.; Mi, K.; Fang, S.; Huang, X.; Li, J.;
et al. Exploration of Clinical Breakpoint of Danofloxacin for Glaesserella parasuis in Plasma and in PELF. Antibiotics 2021, 10, 808.
https://doi.org/10.3390/antibiotics10070808
AMA Style
Xu Z, Huang A, Luo X, Zhang P, Huang L, Wang X, Mi K, Fang S, Huang X, Li J,
et al. Exploration of Clinical Breakpoint of Danofloxacin for Glaesserella parasuis in Plasma and in PELF. Antibiotics. 2021; 10(7):808.
https://doi.org/10.3390/antibiotics10070808
Chicago/Turabian Style
Xu, Zihui, Anxiong Huang, Xun Luo, Peng Zhang, Lingli Huang, Xu Wang, Kun Mi, Shiwei Fang, Xiao Huang, Jun Li,
and et al. 2021. "Exploration of Clinical Breakpoint of Danofloxacin for Glaesserella parasuis in Plasma and in PELF" Antibiotics 10, no. 7: 808.
https://doi.org/10.3390/antibiotics10070808
APA Style
Xu, Z., Huang, A., Luo, X., Zhang, P., Huang, L., Wang, X., Mi, K., Fang, S., Huang, X., Li, J., Yuan, Z., & Hao, H.
(2021). Exploration of Clinical Breakpoint of Danofloxacin for Glaesserella parasuis in Plasma and in PELF. Antibiotics, 10(7), 808.
https://doi.org/10.3390/antibiotics10070808